Heidi Daugherty
Adult Health · Canton, OHNPI 1346497906
Payments from drug & device makers
Across 167 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$331
- Lilly USA, LLC$219
- Corcept Therapeutics$183
- Dexcom, Inc.$159
- Novartis$142
- Sanofi-aventis U.S. LLC$139
- plus $2K from 35 others
What the payments were for
- Food & beverage$2,938100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $331 |
| Lilly USA, LLC | 12 | $219 |
| Corcept Therapeutics | 8 | $183 |
| Dexcom, Inc. | 8 | $159 |
| Novartis | 8 | $142 |
| Sanofi-aventis U.S. LLC | 6 | $139 |
| Abbott | 9 | $137 |
| Bayer | 8 | $136 |
| Boehringer Ingelheim | 9 | $130 |
| Amgen | 7 | $124 |
| Insulet Corporation | 7 | $118 |
| Xeris Pharmaceuticals, Inc. | 5 | $79 |
| Tandem Diabetes Care, Inc. | 5 | $70 |
| Ascendis Pharma Endocrinology Inc | 3 | $63 |
| Pfizer | 4 | $63 |
| Radius Health, Inc. | 3 | $60 |
| Medtronic | 3 | $58 |
| IBSA Pharma Inc. | 4 | $57 |
| BETA Bionics, Inc. | 3 | $55 |
| AstraZeneca(2 entities) | 3 | $54 |
| Amphastar Pharmaceuticals, Inc. | 3 | $53 |
| Nevro Corp. | 2 | $42 |
| Recordati_rare_diseases_inc. | 3 | $37 |
| AbbVie | 2 | $35 |
| Globus Medical | 1 | $33 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $26 |
| Averitas Pharma Inc. | 1 | $26 |
| Vivus LLC | 2 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| GRT US Holding, Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $21 |
| Evoke Pharma, Inc. | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Mannkind Corporation | 1 | $11 |
How this compares
$2,938 in reported general payments places this provider in the 85th percentile of 1,184 adult health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 296 | $318,820 |
| OzempicSemaglutide | 195 | $267,712 |
| TrulicityDulaglutide | 153 | $206,018 |
| JanuviaSitagliptin Phosphate | 103 | $105,058 |
| FarxigaDapagliflozin Propanediol | 94 | $85,170 |
| Tresiba Flextouch U-100Insulin Degludec | 92 | $64,733 |
| Humalog Kwikpen U-100Insulin Lispro | 190 | $64,713 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $62,714 |
| MounjaroTirzepatide | 52 | $60,574 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $59,330 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $48,044 |
| ProliaDenosumab | 27 | $45,710 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 229 | $44,547 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $38,022 |
| Novolog FlexpenInsulin Aspart | 81 | $31,625 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $130 | $334,691316 claims |
| Novo NordiskOzempic, Fiasp, Rybelsus, Novolog, Levemir | $331 | $330,324256 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Baqsimi | $219 | $283,978262 claims |
| AstraZenecaFarxiga | $54 | $85,17094 claims |
| AmgenProlia | $124 | $45,71027 claims |
| AbbVieSynthroid | $35 | $10,466213 claims |
| Sanofi-aventis U.S. LLCLantus | $139 | $10,06834 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $33 | $9,8681,027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,184 adult health providers in Ohio.
Other adult health in Canton
- Bonnie MohlerCanton$338K
- Courtney Ray-MartyCanton$16K
- Kristen BurockCanton$8K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
- Marie ChambersCenterville$134K
- Susan FlickCleveland$131K
- Margaret TiktinCleveland$105K
- Teresa ShafferBoardman$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.